Tikun Olam-Cannbit Pharmaceuticals Ltd (TLV:TKUN)
Israel
· Delayed Price · Currency is ILS · Price in ILA 39.20
+0.80 (2.08%)
Apr 28, 2025, 12:09 PM IDT
TLV:TKUN Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 34.95 | 44.23 | 49.3 | 37.03 | 21.66 | Upgrade
|
| Revenue | 34.95 | 44.23 | 49.3 | 37.03 | 21.66 | Upgrade
|
| Revenue Growth (YoY) | -20.97% | -10.28% | 33.13% | 70.97% | - | Upgrade
|
| Cost of Revenue | 29.53 | 32.7 | 31.19 | 29.38 | 7.37 | Upgrade
|
| Gross Profit | 5.43 | 11.53 | 18.11 | 7.65 | 14.29 | Upgrade
|
| Selling, General & Admin | 12.62 | 22.82 | 23.95 | 27.66 | 28.86 | Upgrade
|
| Research & Development | 0.83 | 3.89 | 5.16 | 7.2 | 2.16 | Upgrade
|
| Other Operating Expenses | -0.12 | -0.64 | -0.33 | 0.85 | 5.07 | Upgrade
|
| Operating Expenses | 19.98 | 39.36 | 44.45 | 50.7 | 46.48 | Upgrade
|
| Operating Income | -14.55 | -27.83 | -26.34 | -43.05 | -32.2 | Upgrade
|
| Interest Expense | -1.88 | -2.3 | -1.77 | -1.28 | -1.19 | Upgrade
|
| Interest & Investment Income | - | 0.13 | 0.09 | 0.01 | 0.05 | Upgrade
|
| Earnings From Equity Investments | - | -0.38 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -16.44 | -30.38 | -28.02 | -44.32 | -33.33 | Upgrade
|
| Impairment of Goodwill | -22.34 | -59.63 | -17.57 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -4.73 | -0.43 | 1.93 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -0.13 | Upgrade
|
| Asset Writedown | - | - | -15.27 | - | - | Upgrade
|
| Legal Settlements | - | - | - | - | -1.35 | Upgrade
|
| Other Unusual Items | 3.4 | -3.56 | 9.79 | 10.29 | -0.21 | Upgrade
|
| Pretax Income | -40.1 | -93.99 | -49.14 | -34.03 | -35.02 | Upgrade
|
| Income Tax Expense | - | 0.03 | 0.01 | - | -0.27 | Upgrade
|
| Earnings From Continuing Operations | -40.1 | -94.02 | -49.15 | -34.03 | -34.75 | Upgrade
|
| Minority Interest in Earnings | 0 | 5.13 | 0.91 | 1.38 | 1.81 | Upgrade
|
| Net Income | -40.1 | -88.89 | -48.24 | -32.65 | -32.94 | Upgrade
|
| Net Income to Common | -40.1 | -88.89 | -48.24 | -32.65 | -32.94 | Upgrade
|
| Shares Outstanding (Basic) | 84 | 63 | 49 | 42 | 34 | Upgrade
|
| Shares Outstanding (Diluted) | 84 | 63 | 49 | 42 | 34 | Upgrade
|
| Shares Change (YoY) | 32.86% | 29.54% | 15.79% | 23.01% | 86.23% | Upgrade
|
| EPS (Basic) | -0.48 | -1.41 | -0.99 | -0.78 | -0.96 | Upgrade
|
| EPS (Diluted) | -0.48 | -1.41 | -0.99 | -0.78 | -0.96 | Upgrade
|
| Free Cash Flow | -3.78 | -4.12 | -23.2 | -33.49 | -50.69 | Upgrade
|
| Free Cash Flow Per Share | -0.04 | -0.07 | -0.48 | -0.80 | -1.48 | Upgrade
|
| Gross Margin | 15.52% | 26.06% | 36.73% | 20.66% | 65.96% | Upgrade
|
| Operating Margin | -41.63% | -62.93% | -53.44% | -116.25% | -148.65% | Upgrade
|
| Profit Margin | -114.73% | -200.97% | -97.85% | -88.17% | -152.09% | Upgrade
|
| Free Cash Flow Margin | -10.82% | -9.31% | -47.07% | -90.43% | -234.05% | Upgrade
|
| EBITDA | 14.22 | 27.56 | 9.2 | -25.89 | -19.89 | Upgrade
|
| EBITDA Margin | 40.69% | 62.32% | 18.66% | -69.92% | -91.84% | Upgrade
|
| D&A For EBITDA | 28.77 | 55.39 | 35.54 | 17.15 | 12.3 | Upgrade
|
| EBIT | -14.55 | -27.83 | -26.34 | -43.05 | -32.2 | Upgrade
|
| EBIT Margin | -41.63% | -62.93% | -53.44% | -116.25% | -148.65% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.